{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-26-003381","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2026-05-13T21:15:17+00:00","discovered_at":"2026-05-13T21:16:01.278106+00:00","generated_at":"2026-05-13T21:17:24.000686+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aptose Q1 net loss $7.6M, cash $4.1M; Hanmi acquisition delayed, TUS data at EHA","bullets":["Net loss of $7.6M ($2.99/share) for Q1 2026 vs $5.5M ($2.61/share) in Q1 2025.","Cash and restricted cash $4.1M; working capital deficit $5.1M; relies on Hanmi advances to fund operations.","Hanmi acquisition delayed due to pending Korean regulatory approvals; target close May 2026 at C$2.41/share (28% premium).","TUS+VEN+AZA triplet data from TUSCANY trial selected for oral presentation at EHA2026 Congress in June.","Luxeptinib license rights returned to CGI; program winding down."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-26-003381","json":"https://secwatch.observer/filing/0001171843-26-003381.json","markdown":"https://secwatch.observer/filing/0001171843-26-003381.md","text":"https://secwatch.observer/filing/0001171843-26-003381.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184326003381/0001171843-26-003381-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184326003381/f8k_051326.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-13T21:17:24.000686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c771d03b4ba321477034ca31fea4ce6f42c3dca0","claim":"Aptose Biosciences Inc. reported the first quarter ended March 31, 2026 results: net income $7.6 million, EPS $(2.99) per common share, basic and diluted.","evidence_excerpt":"Net loss per common share, basic and diluted $ (2.99 )","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882361/000117184326003381/0001171843-26-003381-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"$7.6 million"},{"label":"EPS","value":"$(2.99) per common share, basic and diluted"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}